Nashville, TN, United States of America

R Daniel Beauchamp

USPTO Granted Patents = 4 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2006-2017

Loading Chart...
4 patents (USPTO):Explore Patents

Title: R Daniel Beauchamp: Innovator in E-cadherin Research

Introduction

R Daniel Beauchamp is a notable inventor based in Nashville, TN (US), recognized for his contributions to the field of molecular biology. He holds a total of four patents, focusing primarily on the transcriptional induction of E-cadherin, a crucial protein involved in cell adhesion and signaling.

Latest Patents

Beauchamp's latest patents include innovative compounds such as N-acetamidoalkyl-5-arylisoxazole-3-carboxamide analogs. These compounds serve as mediators of transcriptional induction of E-cadherin. His work also encompasses synthesis methods for creating these compounds, pharmaceutical compositions that include them, and methods for treating disorders associated with E-cadherin activity. Another significant patent involves N-((arylamino)alkyl)-5-arylisoxazole-3-carboxamide analogs, which similarly function as mediators of E-cadherin transcriptional induction.

Career Highlights

Throughout his career, Beauchamp has worked with esteemed institutions, including Vanderbilt University and Atherogenics, Inc. His research has significantly advanced the understanding of E-cadherin and its implications in various disorders.

Collaborations

Beauchamp has collaborated with notable colleagues such as Craig William Lindsley and Alex Gregory Waterson, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

R Daniel Beauchamp's work in the development of E-cadherin mediators showcases his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to addressing critical health issues through molecular research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…